Alto Neuroscience(ANRO.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Alto Neuroscience
ANRO.US
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD.
4.838 T
ANRO.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Alto Neuroscience Secures New Patent for ALTO-207 Depression Treatment, Extending Protection Into Mid-2040s

    Alto Neuroscience Inc. has secured U.S. Patent Number 12,521,374 for its depression treatment ALTO-207, which combines pramipexole and ondansetron. This patent protects the use of ondansetron to reduce side effects from pramipexole, allowing for higher doses to enhance antidepressant effects. The patent is expected to safeguard ALTO-207's intellectual property until the mid-2040s, reinforcing its position in the treatment of resistant depression.

    Reuters·
    US
    ANRO
    +0.88%
    Reuters·
    US
    ANRO
    +0.88%

    Alto Neuroscience Unveils New EEG Biomarker Data Advancing Precision Psychiatry Treatments

    Alto Neuroscience Inc. announced new EEG biomarker data at the 64th Annual Meeting of the American College of Neuropsychopharmacology. Findings included the efficacy of ALTO-203 in improving attention and wakefulness in patients with abnormal theta/beta ratios. The company validated Theta-ITC as a reliable EEG biomarker for cognitive impairment in schizophrenia and developed a biomarker predicting placebo response in major depressive disorder, enhancing treatment effect detection. The results were presented at the ACNP 2026 meeting.

    Reuters·
    US
    ANRO
    +0.88%
    Reuters·
    US
    ANRO
    +0.88%

    Alto Neuroscience Showcases Precision Psychiatry Advances in New Corporate Presentation

    Alto Neuroscience Inc. has unveiled a corporate presentation detailing advancements in its precision medicine portfolio for CNS disorders, including depression, schizophrenia, bipolar depression, and Parkinson’s disease. The company is conducting multiple clinical trials with key data readouts expected in the next two years. Alto's biomarker-based strategy aims to enhance clinical outcomes, and the presentation includes updates on cash runway and study milestones. The full presentation is accessible via a provided link.

    Reuters·
    US
    ANRO
    +0.88%
    Reuters·
    US
    ANRO
    +0.88%

    Chardan Capital Raises Alto Neuroscience (NYSE:ANRO) Price Target to $30.00

    Chardan Capital has raised its price target for Alto Neuroscience (NYSE:ANRO) from $15.00 to $30.00, maintaining a "buy" rating. This new target suggests an 80.67% potential upside from the current price. Other analysts have varied opinions, with Weiss Ratings giving a "sell" rating, while Jefferies Financial Group and BTIG Research have set targets of $25.00 and $27.00, respectively. The stock has an average rating of "Moderate Buy" and a consensus price target of $26.33. Alto Neuroscience focuses on precision medicine for neuropsychiatric disorders.

    Market Beat·
    US
    ANRO
    +0.88%
    Market Beat·
    US
    ANRO
    +0.88%

    Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 33% Above Its Share Price

    Alto Neuroscience, Inc. (NYSE:ANRO) is estimated to be 25% undervalued, with a fair value of $23.71 compared to its current share price of $17.80. Analysts have set a price target of $29.25, indicating a potential upside. The valuation is based on a two-stage Discounted Cash Flow (DCF) model, which estimates future cash flows and discounts them to present value. The total equity value is calculated at $737 million, suggesting the stock is undervalued. However, the DCF model has limitations and relies on assumptions about future performance.

    Simplywall·
    US
    ANRO
    +0.88%
    Simplywall·
    US
    ANRO
    +0.88%
    © 2026 Longbridge｜Disclaimer